<DOC>
	<DOCNO>NCT01329978</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , efficacy sofosbuvir ( GS-7977 ; PSI-7977 ) administer combination pegylated interferon ribavirin ( PEG/RBV ) treatment-naive patient HCV genotypes 1,4,5,6 , indeterminate genotype .</brief_summary>
	<brief_title>Sofosbuvir With Pegylated Interferon Ribavirin Hepatitis C Virus ( HCV ) Genotypes 1,4,5,6</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Males females Chronic Hepatitis C ( HCV ) Genotype 1,4,5,6 , indeterminate Naive previous HCV treatment Positive HBsAg , antiHBc IgM Ab , antiHIV Ab History clinically significant chronic liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>Chronic Hepatitis C</keyword>
</DOC>